L3VLUP
ProSign in

TNDM · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

TNDMLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • TNDM
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterTNDMLLY
Q3 202013 holders, $1.7bn33 holders, $14.1bn
Q4 20206 holders, $1.1bn29 holders, $17.3bn
Q1 20219 holders, $943m24 holders, $23.0bn
Q2 202110 holders, $1.1bn24 holders, $27.8bn
Q3 202113 holders, $1.5bn31 holders, $29.9bn
Q4 202116 holders, $1.9bn31 holders, $34.7bn
Q1 202213 holders, $1.4bn24 holders, $35.3bn
Q2 202210 holders, $740m33 holders, $42.7bn
Q3 20228 holders, $748m31 holders, $43.4bn
Q4 202211 holders, $836m31 holders, $46.6bn
Q1 202310 holders, $411m33 holders, $44.3bn
Q2 20239 holders, $306m37 holders, $59.6bn
Q3 20236 holders, $256m44 holders, $67.6bn
Q4 20238 holders, $388m45 holders, $73.6bn
Q1 20249 holders, $426m41 holders, $95.3bn
Q2 20247 holders, $332m43 holders, $110bn
Q3 20247 holders, $295m45 holders, $107bn
Q4 202410 holders, $188m46 holders, $93.9bn
Q1 20254 holders, $44m42 holders, $98.4bn
Q2 20257 holders, $74m43 holders, $93.2bn
Q3 20256 holders, $64m39 holders, $86.7bn
Q4 20255 holders, $81m41 holders, $123bn
Q1 20265 holders, $69m39 holders, $106bn
Q2 20266 holders, $73m44 holders, $132bn
TNDM

Tandem Diabetes Care Inc

Holders
5
Reported value
$69m
Buyers
16
Sellers
15

Breadth +1 among 91 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
LLY

Eli Lilly & Co

Holders
39
Reported value
$106bn
Buyers
25
Sellers
25

Breadth 0 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2026

Among the 42 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only TNDM (3)

Baillie Gifford & Co, Freestone Grove Partners LP, PDT Partners LLC

Only LLY (37)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Arrowstreet Capital LP, Artisan Partners LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Fidelity (FMR LLC), GAMCO Investors Inc, Harris Associates LP, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Millennium Management LLC, Neuberger Berman Group LLC, Point72 Asset Management LP, and 12 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →